In RET-altered thyroid cancer, Wirth et al. detailed an ORR of 73% and 92% 1-year PFS of 88 untreated MTC patients harboring RET mutations; of 55 other MTC patients who received prior multi-kinase TKIs vandetinib and/or cabozantinib, impressive response rates and durability were still seen [151]. This evidence concerns the gene RET and thyroid gland carcinoma.